

Special Issue

Coronavirus: Vaccines and Other Therapeutics

Message from the Guest Editor

As is well known to the community, the major focus of our journal, *Vaccines* (ISSN 2076-393X) is on laboratory and clinical vaccine research, utilization, and immunization. The Special Issue on “Coronavirus Vaccines and Other Therapeutics” focuses on high-quality research in any basic and/or applied area related to the ongoing coronavirus pandemic. We welcome articles (high-quality reviews, regular research papers, communications, and case reports) contributing either fundamentally or clinically to the concerted effort worldwide to combat the ongoing coronavirus pandemic. In addition to works on the standard vaccination approach, we are also encouraging studies on other therapeutic endeavors, e.g., other modes of immunization, antigen arrest, as well as novel inhibitors. We are also interested in computational approaches, especially those based on direct experimental data, and would appreciate works combining computation and experiments.

Guest Editor

Dr. Sankar Basu

Asutosh College (Under Calcutta University, Kolkata, India), Department of Microbiology & External Scientific Collaborator at the 3BIO group, ULB, Brussels, Belgium

Deadline for manuscript submissions

closed (30 November 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/85423

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).